MedicaidPrior AuthMedium impact
Bortezomib products (Velcade and Bortezomib for injection) (Revised)
Humana·LA · Oncology, Hematology·Medicaid
Effective date
Sep 1, 2025
We identified it
Jun 24, 2026
Summary
Humana Medicaid Louisiana has revised their prior authorization policy for Bortezomib products (Velcade and generic bortezomib injections) used to treat blood cancers including multiple myeloma, mantle cell lymphoma, and Waldenström's macroglobulinemia. The policy establishes specific approval criteria and excludes members who have experienced disease progression on bortezomib-containing regimens.
Action Required
Before September 1, 2025: Billing team and oncology providers must obtain prior authorization for all Bortezomib products (Velcade and generic bortezomib injections) for Humana Medicaid Louisiana members. Ensure documentation includes confirmed diagnosis of multiple myeloma, mantle cell lymphoma, or Waldenström's macroglobulinemia, and verify patient has not experienced disease progression on prior bortezomib therapy. Claims will be denied without proper prior authorization.